Single-arm phase II trial is a key component for developing advanced cancer drug and treatment to target therapy and immunotherapy in which time-to-event endpoints are the primary endpoints. The proposed book provides a comprehensive summary to the most commonly used methods for single-arm phase II trial design with time-to-event endpoints.
Single-arm phase II trial is a key component for developing advanced cancer drug and treatment to target therapy and immunotherapy in which time-to-event endpoints are the primary endpoints. The proposed book provides a comprehensive summary to the most commonly used methods for single-arm phase II trial design with time-to-event endpoints.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Jianrong (John) Wu is a professor in the Division of Cancer Biostatistics, Department of Internal Medicine, University of Kentucky; Biostatistics and Bioinformatics Shared Resource, Markey Cancer Center. Dr. Wu has more than 20 years' experience of designing and conducting cancer clinical trials at St. Jude Children's Research Hospital and Markey Cancer Center and has developed many novel statistical methods for designing and monitoring single-arm phase II and randomized phase III trial design with time-to-event endpoints.
Inhaltsangabe
1. Introduction of Single-Arm Phase II Trial Design 2. Phase II Trial Design Under Parametric Model 3. One-Stage Design Evaluating Survival Probabilities 4. Two-Stage Design Evaluating Survival Probabilities 5. One-Stage Design Evaluating Survival Distributions 6. Two-Stage Design Evaluating Survival Distributions 7. Phase II Immunotherapy Trial Design 8. Phase II Trial Design with GMI Endpoint 9. Bayesian Single-Arm Phase II Trial Design Appendix A. Probability of Failure Under Uniform Accrual Appendix B. Asymptotic Distribution of Nelson-Aalen Estimate of the Cumulative Hazard Appendix C. Derivation Asymptotic Distribution of the OSLRT Appendix D. Derivation of equations (6.8) and (6.9) Appendix E. Crossing point for the mixture cure model Appendix F. Derivation asymptotic distribution of the score test Q Appendix G. Generate random variables from GBVE model Appendix H. Derivation censoring survival distribution of GMI Appendix I. Proof of monotonicity of the posterior probability Appendix J. Relationship between frequentist and Bayesian type I error rates Appendix K. R Code
1. Introduction of Single-Arm Phase II Trial Design 2. Phase II Trial Design Under Parametric Model 3. One-Stage Design Evaluating Survival Probabilities 4. Two-Stage Design Evaluating Survival Probabilities 5. One-Stage Design Evaluating Survival Distributions 6. Two-Stage Design Evaluating Survival Distributions 7. Phase II Immunotherapy Trial Design 8. Phase II Trial Design with GMI Endpoint 9. Bayesian Single-Arm Phase II Trial Design Appendix A. Probability of Failure Under Uniform Accrual Appendix B. Asymptotic Distribution of Nelson-Aalen Estimate of the Cumulative Hazard Appendix C. Derivation Asymptotic Distribution of the OSLRT Appendix D. Derivation of equations (6.8) and (6.9) Appendix E. Crossing point for the mixture cure model Appendix F. Derivation asymptotic distribution of the score test Q Appendix G. Generate random variables from GBVE model Appendix H. Derivation censoring survival distribution of GMI Appendix I. Proof of monotonicity of the posterior probability Appendix J. Relationship between frequentist and Bayesian type I error rates Appendix K. R Code
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
